谷红联合尼莫地平在小血管病性认知障碍与大动脉粥样硬化性认知障碍中的疗效分析

Analysis of the Curative Effect of Guhong Combined with Nimodipine in the Cognitive Impairment of Small Vessel Disease and the Cognitive Impairment of Large Atherosclerosis

目的:谷红联合尼莫地平对小血管病性认知障碍与大动脉粥样硬化性认知障碍进行治疗,考察对两种类型血管性认知障碍的疗效。方法:以2017年-2019年12月就诊于我院血管性认知功能障碍(vascular cognitive impairment,VCI)患者为研究对象,大动脉粥样硬化型(large artery atherosclerotic,LAA)204例,为LAA组,小血管性(small vessel disease,SVD)226例,为SVD组,所有患者均给予基础治疗,在此基础上,LAA组和SVD组均进行谷红注射液和尼莫地平联合治疗,以临床疗效、认知功能评分以及不良反应情况为考察指标,考察谷红联合尼莫地平对两种类型血管性认知障碍的治疗效果。结果:经过谷红注射液联合尼莫地平的治疗,LAA组和SVD组均取得了较好的疗效,LAA组总有效率为90.20%,SVD组总有效率为88.05%,两组总有效率比较,无显著差异(P>0.05);治疗前两组患者的蒙特利尔认知量表(Montreal Cognitive Assessment,MoCA)评分和简易精神状态量表(Mini-Mental State Exam,MMSE)评分均无统计学差异(P>0.05);治疗后,LAA组和SVD组患者的MOCA评分和MMSE评分均显著的改善(P<0.05),其中LAA组MOCA评分由19.31±5.45提升至22.31±6.21,MMSE评分由21.45±5.91提升至25.23±3.21,SVD组MOCA评分由19.28±4.01提升至22.88±5.73,MMSE评分由21.30±7.76提升至25.08±6.19,但两组间各项评分无显著差异(P>0.05);治疗期间LAA组和SVD组均未出现严重不良反应,共有7例患者出现轻度头部胀痛、面部潮红等,其中LAA组3(1.47%)例,SVD组4(1.96%)例,两组间比较无显著差异(P>0.05)。结论:谷红注射液联合尼莫地平治疗小血管病性认知障碍与大动脉粥样硬化性认知障碍,均能显著缓解患者认知功能障碍症状,临床疗效显著,无严重不良反应,有一定的推广价值。

Objective:To investigate the effect of Guhong injection combined with nimodipine on small blood vessel disease cognitive impairment and large artery atherosclerotic cognitive impairment.Methods:Taking VCI patients who were treated in our hospital from 2017 to December 2019 as the research object,204 cases of LAA type were in the LAA group,and 226 cases of SVD type were in the SVD group.All patients were given basic treatment.On this basis,the LAA group and the SVD group were treated with Guhong injection and nimodipine.The clinical efficacy,cognitive function scores and adverse reactions were used as indicators to investigate the therapeutic effect of Guhong combined with nimodipine on two types of vascular cognitive impairment.Results:After the treatment of Guhong injection combined with nimodipine,the LAA group and the SVD group achieved good results.The total effective rate in the LAA group was 90.20%,and the total effective rate in the SVD group was 88.05%.There was no significant difference in total effective rate between the two groups(P>0.05).There was no statistical difference between the MOCA score and MMSE score of the two groups before treatment(P>0.05).After treatment,the MOCA score and MMSE score of the patients in the LAA group and the SVD group were significantly improved(P<0.05).The MOCA score in the LAA group increased from 19.31±5.45 to 22.31±6.21,and the MMSE score increased from 21.45±5.91 to 25.23±3.21,the MOCA score of the SVD group increased from 19.28±4.01 to 22.88±5.73,and the MMSE score increased from 21.30±7.76 to 25.08±6.19,but there was no significant difference in the scores between the two groups(P>0.05).During the treatment period,neither the LAA group nor the SVD group had serious adverse reactions.A total of 7 patients had mild head pain and facial flushing,among which 3(1.47%)cases in the LAA group and 4(1.96%)cases in the SVD group There was no significant difference between the groups(P>0.05).Conclusion:Guhong injection combined with nimodipine in the treatment of small blood vessel cognitive impairment and large artery atherosclerotic cognitive impairment can significantly alleviate the symptoms of cognitive dysfunction in patients.The clinical effect is remarkable,there is no serious adverse reaction,and it has certain promotion value.